Work

Supplementary Table S4 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer

Year: 2024

Type: supplementary-materials

Abstract: Table S4. Pharmacokinetic exposure summary. AUC, area under the curve; Ceoi, concentration at end of infusion; Ctrough, concentration at the end of the dosing interval; CV, coefficient of variation; NA, not applicable; popPK, population pharmacokinetic; SD, standard deviation.

DOI: 10.1158/1078-0432.25324488.v1

Authors: Ana Oaknin, Sharad A. Ghamande, Yuka Kasamatsu, Marta Gil-Martin, Juan Francisco Grau-Bejar, Carmen Garcia-Duran, Masashi Sato, Abdul Siddiqui, Surendra Pal Chaudhary, Yulia Vugmeyster, Kosei Hasegawa

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392356680

Cites:

Cited by:

Related to: 10